Base excision repair (BER) plays a critical role in the repair of bases damaged by oxidative metabolism or alkylating agents, such as those commonly used in cancer therapy. Incomplete BER generates intermediates that require activation of homology-dependent DNA repair to resolve. We investigated the effects of lithocholic acid (LCA), an inhibitor of the key BER enzyme DNA polymerase β (pol β), in cells deficient in expression of the homology-dependent repair factor BRCA2. In vitro studies show that LCA suppresses the DNA polymerase and 5′-deoxyribose phosphate lyase activities of DNA pol β by preventing the formation of a stable pol β-DNA complex, reducing BER effectiveness. Cytotoxicity assays based on colony formation revealed that LCA exhibits synergism with the alkylating agent temozolomide, which engages BER through DNA methylation, and that the degree of synergism is increased in cells lacking functional BRCA2. BRCA2-deficient cells also showed heightened susceptibility to both LCA and temozolomide individually. The potentiation of temozolomide cytotoxicity by LCA owes to the conversion of single-stranded DNA breaks generated through incomplete BER of methylated nucleotides into double-stranded breaks during DNA replication, as indicated by γH2AX immunofluorescence. Death seems to be induced in cotreated cells through an accumulation of persistent doublestranded DNA breaks. Mutations of the BRCA2 gene have been extensively characterized and are present in various cancers, implying that inhibition of BER may offer a means to augment tumor selectivity in the use of conventional cancer therapies. Cancer Res; 70(1); 409-17. ©2010 AACR.
Introduction
Lithocholic acid (LCA), a secondary bile acid, has previously been identified as a potent inhibitor of mammalian DNA polymerase β (pol β; ref. 1). In the absence of pol β, the base excision repair (BER) pathway is defective (2) . BER is essential to the maintenance of genomic integrity, particularly with respect to oxidative damage and alkylation-induced lesions (3, 4) . Pol β has also been shown to catalyze the removal of a 5′-deoxyribose phosphate (5′-dRP) group during short-patch (single-nucleotide gap) BER when base damage is recognized by a monofunctional DNA glycosylase (5) . Inhibition of either the DNA polymerase or 5′-dRP lyase functionalities of pol β can therefore result in termination of short-patch BER.
The oral alkylating agent temozolomide has been extensively studied in the treatment of various tumors, including glioblastoma multiforme, metastatic melanoma, and refractory anaplastic astrocytoma (6) (7) (8) (9) (10) . The antineoplastic efficacy of temozolomide is dependent on its ability to methylate DNA, primarily at the targets O 6 -guanine, N 7 -guanine, and N 3 -adenine (11) . Recent work has shown that inhibition of poly(ADP-ribose) polymerase (PARP) activity potentiates the cytotoxic effects of temozolomide (12, 13) . As the PARP family member PARP-1 functions to detect single-stranded DNA breaks (SSB) and is required for recruitment of proteins to promote efficient BER (14, 15) , the observed potentiation is presumably attributable to an inability to complete BER of deleterious methyl adducts.
Our goal was to determine whether disruption of the BER pathway through the inhibitory effect of LCA on pol β would produce a similar sensitivity to temozolomide-induced DNA methylation. We further hypothesized that synergism of LCA with temozolomide would be increased in cell lines lacking the ability to efficiently repair double-stranded DNA breaks (DSB), owing to inactivation of the homology-dependent DNA repair (HDR) pathway. HDR uses homologous regions of DNA to repair DSBs and is typically considered to be an error-free pathway, in contrast to more error-prone pathways such as nonhomologous end joining (16) . HDR resolves collapsed replication forks that may arise from SSBs, such as those resulting from failed BER. To this end, we explored the individual and combined effects of LCA and temozolomide in cell lines deficient in expression of the critical HDR factor, BRCA2.
The BRCA2 protein functions as a tumor suppressor through its involvement in the process of DSB repair via homologous recombination (17) (18) (19) . BRCA2 interacts directly with RAD51 and facilitates the formation of helical RAD51-ssDNA filaments, which localize to template DNA to initiate repair (20, 21) . Hereditary germ-line mutations in the BRCA2 gene contribute a significant predisposition to breast and ovarian cancers, arising from increased genetic instability and subsequent cellular transformation as a result of inefficient HDR (22) (23) (24) . Additionally, BRCA2 silencing and mutational inactivation can contribute to sporadic tumorigenesis (25, 26) . Thus, BRCA2-deficient cancers represent an attractive target for synergistic drug therapy.
Materials and Methods
Cell lines. VC-8 (BRCA2-deficient) and VC-8+BRCA2-complemented Chinese hamster ovary (CHO) cells were a gift of Dr. Graeme C.M. Smith (KuDOS Pharmaceuticals Ltd., Cambridge, United Kingdom) and were maintained in DMEM supplemented with 10% fetal bovine serum (FBS). EUFA423 (BRCA2-deficient) and EUFA423+BRCA2-complemented human fibroblasts were a gift of Dr. Simon Powell (Memorial Sloan-Kettering Cancer Center, New York, NY) and were maintained in DMEM supplemented with 10% FBS, 20 mmol/L HEPES, and 500 mg/mL G418 (complemented only). Mouse embryonic fibroblast (MEF) cell lines 92TAg [wild-type (WT)] and 308TAg (Aag −/− ) were a gift of Dr. Leona
Samson (Massachusetts Institute of Technology, Cambridge, MA) and were maintained in DMEM supplemented with 10% FBS and L-glutamine. All cells were cultured at 37°C in a 5% CO 2 atmosphere. Transfection, infection, and expression analysis. To infect the MEFs, the WT pol β and E295K constructs were packaged into retroviruses using the GP2-293 viral packaging cell line. Exponentially growing MEFs at ∼50% confluence in 60-mm dishes were incubated with 1 mL of virus with 1 μg/mL polybrene (Sigma) for 2 h. The medium was then removed and replaced with fresh medium containing 1 μg/mL polybrene. After an overnight incubation, cells were split into 100-mm dishes at different cell densities. All dishes were incubated overnight and then supplemented with 400 μg/mL hygromycin B (Invitrogen) to select clones with stably integrated constructs. Tetracycline (Sigma) at a concentration of 4 μg/mL was also present in the medium to repress expression of the WT or E295K proteins. Individual cell colonies were cloned using cloning cylinders and expanded in the same growth medium.
Chemicals. LCA and temozolomide were purchased from Sigma-Aldrich. Stocks (100 mmol/L) in DMSO were prepared fresh before each experiment, diluted as necessary, and added to culture medium at 0.1% (v/v). All culture medium was limited to 5% FBS during drug treatment to inhibit LCA precipitation. Ultrapure deoxynucleoside triphosphates, ATP, and [γ- were purchased from New England Biolabs. Sodium borohydride was purchased from Sigma-Aldrich.
Preparation of DNA substrates. Oligonucleotides were synthesized by the W. M. Keck Facility at Yale University. The substrates used were 45AG (GCCTCGCAGCCGTCCAAC-CAAC_CAACCTCGATCCAATGCCGTCC) and LPSD (CTGCAGCTGATGCGCUGTACGGATCCCCGGGTAC). The primer oligonucleotide was labeled at the 5′-end with T4 polynucleotide kinase and [γ-
32 P]ATP. Other oligonucleotides were 5′-end phosphorylated with the kinase and cold ATP. After purification on a Bio-Rad spin column to remove unincorporated deoxynucleotide triphosphates, annealing was performed by mixing phosphorylated template, radiolabeled primer, and phosphorylated downstream oligos in 50 mmol/L Tris-HCl (pH 8.0) containing 0.25 mol/L NaCl. The mixture was incubated sequentially at 95°C (5 min), slowly cooled to 50°C (for 30 min) and 50°C (for 20 min), and immediately transferred to ice. To verify proper hybridization, the product was analyzed on an 18% native polyacrylamide gel followed by autoradiography to assess the quality of annealing.
In vitro primer extension assay. Primer extension experiments were conducted in a solution containing 50 mmol/L TrisHCl buffer (pH 8.0), 5 mmol/L MgCl 2 , 2 mmol/L DTT, 20 mmol/ L NaCl, 10% glycerol, and 25 μmol/L dTTP. Enzyme/1-bpgapped DNA mix (10 nmol/L/5 nmol/L) was incubated first with various concentrations of LCA (0-100 μmol/L) and DMSO as control. The enzyme-DNA mixes were incubated with dTTP-MgCl 2 and reactions were carried out at 37°C for 20 min, after which they were stopped by addition of an equal volume of 90% formamide dye and 0.3 mol/L EDTA. Samples were resolved by electrophoresis on 20% polyacrylamide gels containing 8 mol/L urea and then visualized and quantified using a Storm 860 PhosphorImager (Molecular Dynamics, Inc.).
Preparation of 5′-dRP substrate. The 3′-end of DNA substrate LPSD, which contained a single U at position 19 from 3′-end, was radiolabeled using [α-32 P]ATP and terminal transferase and annealed with its complementary oligonucleotide. This DNA duplex was treated with UDG (2 units/1 pmol DNA) in 50 mmol/L HEPES (pH 7.5) at 37°C for 10 min followed by treatment with human APE1 (2 units/1 pmol DNA) in buffer R (10 mmol/L MgCl 2 , 20 mmol/L KCl, and 2 mmol/L DTT) at 37°C for 15 min, which incises the phosphodiester backbone on the 5′-side of the AP site and leaves a 3′-OH and a 5′-dRP residue. Due to the labile nature of the AP site, the 5′-dRPcontaining DNA substrate was prepared just before use.
5′-dRP lyase assay. The assay was set up according to Haracska and colleagues (27) Reactions were incubated at 37°C for 10 min. Various concentrations of LCA (0-100 μmol/L) were added to a standard dRP lyase assay. The reaction product was stabilized by the addition of 2 mol/L sodium borohydride to a final concentration of 340 mmol/L followed by incubation on ice for 30 min. Stabilized (reduced) DNA products were ethanol precipitated in the presence of 0.1 μg/mL tRNA and resuspended in water and an equal volume of formamide dye was added. These products were resolved on a 20% polyacrylamide gel and visualized with a Storm 860 PhosphorImager.
BER assay. 5′-End-labeled LPSD substrate was used as a BER substrate. For reconstituted BER with purified proteins, we followed the method as described by Haracska and colleagues (27) Gel mobility shift assay. Various concentrations of WT pol β protein (0.1-1,000 nmol/L) and 150 μmol/L LCA were incubated with 0.1 nmol/L radiolabeled gapped DNA substrate in buffer containing 50 mmol/L Tris-HCl (pH 8.0), 100 mmol/L NaCl, 10 mmol/L MgCl 2 , and 10% glycerol at room temperature (23°C) for 15 min. Samples were loaded onto a 6% native polyacrylamide gel with the current running at 300 V at 4°C. After the sample was loaded, the voltage was reduced to 150 V. Bound protein was quantified using ImageQuant software after scanning the gel using a Storm 860 PhosphorImager. Protein bound to DNA resulted in a shift of the DNA on the gel when compared with DNA without bound protein. Immunofluorescence. VC-8 and VC-8+BRCA2-complemented cells were seeded onto UV-irradiated coverslips (Corning) and allowed to adhere for 24 h and then cotreated with LCA and temozolomide for 3 h. Cells were either prepared immediately or following a 24-h recovery in untreated medium to allow DSB repair. Procedures were performed under reduced light and all washes used 1× PBS. The culture medium was aspirated and cells were washed once and fixed with 4% formaldehyde for 20 min at room temperature and then washed again. Cells were blocked with 0.5% Triton X-100 buffer containing 3% bovine serum albumin (BSA) for 10 min at room temperature and then incubated with the following antibodies in PBS containing 3% BSA for 20 min at 37°C, with multiple washes after each step: rabbit anti-γH2AX antibody (1:500; Bethyl Laboratories) and FITC-conjugated F(ab′) 2 fragment donkey anti-rabbit IgG (H+L) (1:100; Jackson ImmunoResearch). Cells were then stained with 100 ng/mL 4′,6-diamidino-2-phenylindole (DAPI; Sigma) for 1 min at room temperature and washed, and the coverslips were mounted on microscope slides using a 90% glycerol/10% PBS solution containing 0.01% p-phenylenediamine. Images were captured using an Axiovert 200 microscope (Carl Zeiss MicroImaging, Inc.).
Clonogenic survival assays. All cell lines were plated in triplicate at 500 to 1,000 per well in six-well plates to provide an optimal counting density. Cells were treated with temozolomide for 24 h and with LCA for the entirety of the assay. Cells were cultured for 1 to 2 wk until well-defined colonies had formed, replacing culture medium every 2 to 3 d. Cells were briefly permeabilized with 0.9% saline solution and stained with crystal violet in 80% methanol. Colonies of ≥50 cells were then counted visually. Data points represent the average of the three values and error bars represent the SD.
Results
LCA reduces BER activity via inhibition of pol β. LCA has been previously shown to inhibit the polymerase activity of pol β. We verified that LCA inhibits pol β-catalyzed DNA polymerization in a dose-dependent manner by assaying the repair of 45AG DNA substrate, which contains a 1-nucleotide gap. Polymerase activity was almost completely absent at an LCA concentration of ≥60 μmol/L (Fig. 1A) . We further showed that LCA inhibits 5′-dRP lyase catalysis by pol β using a prototypical lyase assay (Fig. 1B) . A mixture of pol β and 5′-dRP substrate was allowed to react in the presence of increasing concentrations of LCA. In the presence of 60 μmol/L LCA, product formation was reduced to 30% of baseline levels, indicating a similar dose response as for polymerase activity (Fig. 1B) .
To assess whether this inhibition could be directly attributed to the inability of pol β to form a stable complex with DNA in the presence of LCA, the binding of pol β to a DNA substrate containing a 1-nucleotide gap was assayed (Fig. 1C  and D) . The DNA dissociation constant (K D DNA) of WT pol β has been previously established to be 12 ± 2 nmol/L (28). In the presence of DMSO vehicle alone, the K D DNA increases to 78 ± 14 nmol/L. At 150 μmol/L LCA, the binding of pol β to DNA was dramatically reduced, and the K D DNA of pol β could not be determined, suggesting that no stable protein-DNA interaction is occurring.
We hypothesized that the inhibitory action of LCA on both the polymerase and 5′-dRP lyase functionalities of pol β represented an effective mechanism to inhibit the BER pathway. To determine the degree to which BER could be reduced by LCA, the repair of a DNA substrate containing a 1-nucleotide gap was assayed in the presence of pol β, apurinic/apyrimidinic endonuclease, and T4 DNA ligase (Fig. 2A) . The lower bands on the gel represent the starting DNA substrate before (n) and after (n+1) polymerization by pol β, whereas the highest band represents the completely repaired DNA product. The levels of each are represented by the band intensity. Complete BER of the substrate was reduced by 37.2% on the addition of 60 μmol/L LCA relative to DMSO control (Fig. 2B) .
LCA and temozolomide synergism is increased in BRCA2-deficient cells. The HDR pathway is the primary cellular mechanism for error-free repair of DSBs and collapsed replication forks. We wished to determine whether inhibition of BER by LCA, with or without engagement of BER by the alkylating agent temozolomide, would result in increased toxicity in HDR-deficient cells compared with HDR-proficient cells. We reasoned that blocking BER would yield strand-break intermediates that required HDR for resolution. We therefore treated human and CHO cell lines deficient in BRCA2 with increasing concentrations of LCA and/or temozolomide in clonogenic assays. Cells were treated with temozolomide for 24 hours or with LCA for the duration of the assay.
In the BRCA2-deficient VC-8 CHO and EUFA423 human fibroblast cell lines, both LCA and temozolomide individually exhibited increased cytotoxicity over the entire dose range relative to paired cell lines complemented with WT BRCA2 (Fig. 3A and B, respectively) . Differences between the deficient and complemented lines were analyzed statistically via the Wilcoxon signed-rank test and were significant at the P < 0.001 level for LCA and temozolomide treatment in VC-8 and temozolomide treatment in EUFA423 and at the P < 0.005 level for LCA treatment in EUFA423. The data thus imply that the frequency of endogenous DNA lesions leads to sufficiently high levels of SSBs in the presence of LCA to yield lower cell survival when these breaks are converted to DSBs and remain unrepaired by HDR. Similarly, the potency of temozolomide as an alkylating agent allows for sufficient quantities of methyl adducts to be generated and lead to unrepaired DNA lesions even in the presence of a functional BER pathway, conferring an increased sensitivity in BRCA2-deficient cell lines.
Having established BRCA2-deficient cell lines as susceptible to both LCA and temozolomide individually, we hypothesized that the two agents would exhibit a synergistic effect by creating an inability to complete the repair of any methyl adducts formed. Stalling and subsequent collapse of replication forks as cells containing unrepaired SSBs (owing to ineffective BER) progressed into S phase and began to undergo DNA replication would provide an increased frequency of DSBs. Cells were treated with temozolomide for 24 hours or LCA for the duration of the assay or both, and clonogenic survival was measured. Synergism was assessed mathematically using the Chou-Talalay mutually nonexclusive model (29) . When data are fit using this method, combination index (CI) values <1, 1, and >1 are indicative of synergism, additive effect, and antagonism, respectively. At 10 μmol/L temozolomide and 60 μmol/L LCA, VC-8 and VC-8+BRCA2 cells yielded CI values of 0.43 and 0.79, respectively (Fig. 3B) . At 20 μmol/L temozolomide and 80 μmol/L LCA, EUFA423 and EUFA423 +BRCA2 yielded CI values of 0.58 and 0.71, respectively (Fig. 3D) . The model thus indicates synergism between LCA and temozolomide in each cell line examined and suggests that the synergism was greater in BRCA2-deficient cells relative to BRCA2-complemented cells in both sets of paired lines.
Additional cell lines deficient in the HDR factors FANCA (PD220) and BRCA1 (UWB1.289) were also investigated and were weakly sensitive to temozolomide individually but showed no significant increase in LCA/temozolomide synergism relative to cell lines complemented with the respective HDR proteins (data not shown).
The in vivo effectiveness of LCA is specifically related to pol β inhibition. To assess whether the synergism of LCA with temozolomide in BRCA2-deficient cells is directly attributable to inhibition specifically of pol β rather than another polymerase target, we used MEF cell lines exogenously expressing either WT pol β or the dominant-negative E295K Figure 2 . Inhibition of BER by LCA. A, 45AG DNA substrate was incubated with pol β, apurinic/apyrimidinic endonuclease (APE), T4 DNA ligase, and increasing concentrations of LCA to measure BER activity. Formation of n+1 product and repaired BER product was analyzed via gel electrophoresis. B, BER product obtained at each LCA concentration, normalized to untreated sample. mutant of pol β, which has previously been shown to render cells deficient in BER (30) .
We treated the two cell lines with temozolomide in the presence of either 50 μmol/L LCA or DMSO vehicle alone and observed the response in a clonogenic survival assay. In the cells expressing WT pol β, there was a significant difference in survival at the P < 0.05 level depending on the treatment or not with LCA (Fig. 4A) . However, in the cells also expressing the E295K dominant-negative mutant pol β, no significant difference was observed between LCA-or DMSO-treated cells, indicating that the effect of LCA is eliminated when the BER capacity of pol β is already inhibited by the dominant-negative pol β variant. Approximately 80% of the lesions induced by temozolomide are N-methylated purines (31) . Alkyladenine DNA glycosylase (AAG) is the primary DNA glycosylase responsible for recognizing temozolomideinduced DNA lesions, and its knockout serves to mitigate temozolomide cytotoxicity by preventing the creation of abasic sites. In an AAG-null background (308 cells), the overall levels of survival are higher compared with the AAG-WT cells for each experimental condition (Fig. 4B) . This is as expected, because, in the absence of AAG, the production of abasic sites as an initial step in BER is substantially reduced, and so survival is improved (although such cells will likely have increased mutation rates). However, as with the AAG-WT cells, in the AAG-null cells expressing WT pol β, there is still an effect of LCA on survival to temozolomide. In contrast, in the cells expressing the dominant-negative pol β, there is no effect of LCA, again showing that the potentiation of temozolomide cytotoxicity by LCA depends specifically on a functional pol β. These data strongly indicate that pol β inhibition is the underlying mechanism for potentiation of temozolomide by LCA rather than an effect on another polymerase or other cellular target.
LCA and temozolomide cotreatment produces persistent DSBs in the absence of BRCA2. Immunofluorescence analysis of phosphorylated histone H2AX (γH2AX) foci formation was used to measure DSB accumulation in LCA-and temozolomide-treated VC-8 (BRCA2-deficient) and VC-8+BRCA2-complemented cells (Fig. 5A) . The cells were treated for 3 hours and were analyzed either immediately or following a 24-hour recovery period to facilitate DNA repair and allow all cells to enter S phase. Relatively low frequencies of γH2AX foci were observable immediately following treatment and occurred at similar levels in both cell lines (Fig. 5B) . Treatment with DMSO vehicle or 20 μmol/L LCA induced fewer γH2AX foci than treatment with 20 μmol/L temozolomide or 20 μmol/L LCA + 20 μmol/L temozolomide.
Following the 24-hour recovery period, continued DSB generation and persistence was markedly higher in VC-8 than in VC-8+BRCA2. When treated with temozolomide alone, foci levels in VC-8+BRCA2 cells fell by 33% after 24 hours, whereas foci levels in VC-8 cells rose by 157%. Under combined LCA and temozolomide treatment, foci levels in VC-8 +BRCA2 cells fell by 48% and foci levels in VC-8 cells rose by 280%. The data agree with our prediction that in the absence of HDR, DSBs produced by LCA and/or temozolomide treatment remain unrepaired and the quantity of cells exhibiting γH2AX foci increases as more cells enter S phase and additional breaks are generated. In cells with intact BRCA2 expression, the HDR pathway actively repairs DSBs soon after they occur, reducing the number of cells exhibiting γH2AX foci at the 24-hour time point. In addition, the results show that pol β inhibition by LCA leads to even greater generation of DSBs, as would be expected from the higher levels of unrepaired BER intermediates.
Neutral pH comet assays were also used to assess the generation of LCA-and/or temozolomide-induced DSBs in BRCA2-deficient cells and yielded results consistent with γH2AX immunofluorescence (data not shown). Under neutral pH conditions, the DNA is not subjected to alkaline unwinding and the assay does not detect SSBs. Increased comet tail moments therefore indicate a greater quantity of DSBs in cells.
Discussion
The discovery of novel chemotherapeutic adjuvants represents an important step toward improving options for cancer treatment. Here, we have shown that LCA can be used to potentiate the effectiveness of a well-known chemotherapeutic agent in cells exhibiting a prevalent tumorigenic mutation. We observed that LCA reduces BER activity via inhibition of the DNA polymerase and the 5′-dRP lyase activities of pol β. γH2AX immunofluorescence shows that LCA and temozolomide cotreatment generates persistent DSBs that can only be repaired effectively when the HDR pathway is functional. To the best of our knowledge, this is also the first study to show the increased susceptibility of BRCA2-deficient cell lines to treatment with temozolomide or LCA.
The BER pathway has previously been identified as a target for temozolomide potentiation using inhibitors of the PARP protein family (12, 13) . Our work serves to corroborate molecular targeting of BER as a viable methodology in cancer therapy. Although the PARP enzymes PARP-1 and PARP-2 are known to promote BER activity, their specific roles within the pathway remain uncharacterized. The biochemical function of pol β and the effects of its inactivation on BER have been extensively documented (32) (33) (34) (35) . We show here that the DNA polymerase and 5′-dRP lyase functionalities of pol β in short-patch BER represent distinct targets of LCA inhibition. The inability of pol β to complex with template DNA in the presence of LCA is consistent with earlier nuclear magnetic resonance characterization showing that pol β-LCA interaction occurs through the NH 2 -terminal 8-kDa template-binding domain of pol β but not the 31-kDa catalytic domain (36) .
Temozolomide generates a relatively narrow spectrum of DNA base damage. N 7 -methylguanine (N 7 -MeG) and N 3 -methyladenine (N 3 -MeA), composing ∼80% of the induced lesions, are recognized by DNA glycosylases and are therefore substrates for the BER pathway (37, 38) . In addition to exogenous damage, an average cell may experience as many as 10,000 spontaneous DNA lesions each day (39) . Temozolomide cytotoxicity in HDR-deficient cells seems to be a result of the inability of BER to efficiently repair the vast number of exogenous and endogenous lesions, leading to the accumulation of BER intermediates and subsequent formation of DSBs. The γH2AX immunofluorescence data presented here show that temozolomide treatment leads to persistent DSBs even in the absence of LCA inhibition, which are likely responsible for cytotoxicity through induction of apoptotic pathways. The toxicity of LCA alone presumably relies on the frequency of endogenous lesions to generate DSBs. BRCA2-deficient cells are more susceptible to LCA than proficient cells, and this sensitivity is increased when also treated with temozolomide.
The lowered efficacy of temozolomide treatment in some tumors has generated much interest in cellular pathways mediating DNA alkylation resistance. Promoter methylation of the gene encoding O
6
-methylguanine (O 6 -MeG)-DNA methyltransferase (MGMT), which directly repairs the temozolomide-induced O 6 -MeG lesion, is associated with improved prognosis and increased sensitivity to alkylation treatment (40) (41) (42) . Because the predominant N 7 -MeG and N 3 -MeA lesions are BER rather than MGMT substrates, inhibition of BER activity could potentially enhance the effectiveness of temozolomide as a chemotherapeutic agent by increasing the number of lesions that progress into DSBs. The use of LCA and other BER inhibitors as adjuvants to treatment with temozolomide or similar alkylating agents offers a promising means to increase efficacy in resistant tumors. Besides LCA, we have also tested the chemically related betulinic acid and oleanolic acid. However, neither yielded differential effects on BRCA2-deficient versus BRCA2-proficient cell lines (data not shown).
Defects in HDR represent a significant subset of tumorigenic germ-line mutations. Certain inherited loss-of-function mutations in BRCA1 and BRCA2 have been reported to confer as high as 81% and 85% risks of breast cancer and 54% and 23% risks of ovarian cancer by age 80, respectively, whereas the lifetime risks of breast and ovarian cancer among women in general have been estimated at 12.5% and 1.8% (43, 44) . Evidence is also accumulating for the involvement of BRCA2 mutations in predisposition to numerous other cancers in both males and females (45) (46) (47) . BRCA2 is also known to play a role in sporadic tumorigenesis, as it is silenced by binding of the EMSY protein to exon 3 in sporadic breast and ovarian cancer, in which the EMSY gene is amplified in 13% and 17% of tumors, respectively (26) . This amplification leads to increased silencing of the BRCA2 gene and has been correlated with a negative disease prognosis (48) . Treatment strategies specifically exploiting inefficient HDR in BRCA2-deficient tumors thus have the potential to improve the specificity and efficacy of cancer therapy while simultaneously minimizing healthy tissue toxicity.
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